Could a blood vessel drug help tame giant cell arteritis?
NCT ID NCT06957002
First seen May 10, 2026 · Last updated May 30, 2026 · Updated 8 times
Summary
This study tests whether adding bosentan to standard steroid treatment helps people with giant cell arteritis (GCA) stay relapse-free longer and use less steroids. About 40 adults with GCA will receive either bosentan plus steroids or steroids alone for 3 months, then be followed for a year. The goal is to see if the combination reduces flares and allows safer steroid tapering.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre
Paris, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.